First-in-human feasibility study of the aXess graft (aXess-FIH): 6-Month results
The Journal of Vascular Access · 2025
DOI: 10.1177/11297298231220967 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Vascular Access, 2025. Verfasst von Matteo Tozzi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Unit, Department of Medicine and Surgery, Insubria University and Research Center, Varese, Italy. Hauptthemen laut MEDLINE: Arteriovenous Shunt, Surgical, Renal Dialysis, Blood Vessel Prosthesis, Blood Vessel Prosthesis Implantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Xeltis BV.
Abstract (Originalsprache)
Objective
The creation of an arteriovenous fistula (AVF) is considered the most effective hemodialysis (HD) vascular access. For patients who are not suitable for AVF, arteriovenous grafts (AVGs) are the best access option for chronic HD. However, conventional AVGs are prone to intimal hyperplasia, stenosis, thrombosis, and infection. Xeltis has developed an AVG as a potential alternative to currently available AVGs based on the concept of endogenous tissue restoration. The results of the first 6-month follow-up are presented here.
Methods
The aXess first-in-human (FIH) study [NCT04898153] is a prospective, single-arm, multicenter feasibility study that evaluates the early safety and performance of the aXess Hemodialysis Graft. A total of 20 patients with end-stage renal disease were enrolled across six European investigational sites.
Results
At 6-months follow-up, all grafts were patent with primary and secondary patency rates were 80% and 100%, respectively. Three patients required a re-intervention to maintain graft patency, while one re-intervention was required to restore patency. One graft thrombosis and zero infections were reported.
Conclusion
The expected advantages of the novel aXess Hemodialysis Graft over conventional AVGs would be evaluated by the analysis on long-term safety and effectiveness during the 5-year follow-up of the currently ongoing trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vascular Unit, Department of Medicine and Surgery, Insubria University and Research Center, Varese, Italy.
- Department of Vascular Surgery, AZ-Sint Jan Brugge, Bruges, Belgium.
- Pauls Stradins Clinical University Hospital, Riga, Latvia.
- Renal Division, Ghent University Hospital, Ghent, Belgium.
- Department of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
- Department of Thoracic and Vascular Surgery, Ziekenhuis Oost-Limburg, Genk, Belgium.
ORCID-Profile: Matteo Tozzi, An S De Vriese
Förderung
- Xeltis BV
Zitieren
APA
Tozzi, M., De Letter, J., Krievins, D., Jushinskis, J., D'Haeninck, A., Rucinskas, K., Miglinas, M., Baltrunas, T., Nauwelaers, S., De Vriese, A. S., Moll, F., & Vermassen, F. (2025). First-in-human feasibility study of the aXess graft (aXess-FIH): 6-Month results. The Journal of Vascular Access. https://doi.org/10.1177/11297298231220967
Vancouver
Tozzi M, De Letter J, Krievins D, Jushinskis J, D'Haeninck A, Rucinskas K, et al. First-in-human feasibility study of the aXess graft (aXess-FIH): 6-Month results. The Journal of Vascular Access. 2025. doi:10.1177/11297298231220967
BibTeX
@article{Tozzi2025,
author = {Tozzi, Matteo and De Letter, Jan and Krievins, Dainis and Jushinskis, Janis and D'Haeninck, Annick and Rucinskas, Kestutis and Miglinas, Marius and Baltrunas, Tomas and Nauwelaers, Sigi and De Vriese, An S and Moll, Frans and Vermassen, Frank},
title = {First-in-human feasibility study of the aXess graft (aXess-FIH): 6-Month results},
journal = {The Journal of Vascular Access},
year = {2025},
doi = {10.1177/11297298231220967}
}
EUVIMED